Completed

Phase Not Applicable
Age: 13Years +
All Genders
ID00000666

A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection

Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2012-10-29

600

Participants Needed

16

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

To evaluate pyrimethamine as a prophylactic agent against toxoplasmic encephalitis in individuals who are coinfected with HIV and latent Toxoplasma gondii. Toxoplasmic encephalitis is a major cause of illness and death in AIDS patients. Standard treatment for toxoplasmic encephalitis is to combine pyrimethamine and sulfadiazine. Continuous treatment is necessary to prevent recurrence of the disease, but constant use of pyrimethamine/sulfadiazine is associated with toxicity. Clindamycin has been shown to be effective in treatment of toxoplasmic encephalitis in animal studies. This study evaluates pyrimethamine as a preventive treatment against toxoplasmic encephalitis (per 3/26/91 amendment, clindamycin arm was discontinued).

CONDITIONS

Official Title

A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection

Who Can Participate

Age: 13Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

Inclusion Criteria

Concurrent Medication:

Required:

  • Prophylactic treatment for Pneumocystis carinii pneumonia with aerosolized pentamidine, dapsone, or trimethoprim / sulfamethoxazole.

Allowed:

  • Most medications not specifically excluded.

Prior Medication:

Allowed:

  • Antivirals.
  • Antiretrovirals.

Patients:

  • Must be HIV positive or have an AIDS-defining illness OR be at known risk for HIV infection and have a CD4 cell count < 200/mm3 and no other known immunosuppressive disease.
  • Must have positive titer for Toxoplasma gondii.
  • Must be or become a patient of a CPCRA physician.
  • May participate in other clinical trials as long as there is no potential activity against Toxoplasma gondii or cross-toxicity among study drugs.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

  • History of ocular, pulmonary, or central nervous system (CNS) toxicity.
  • CNS lesions.
  • Neurologic deficits except peripheral neuropathy.
  • Mild, moderate, severe, or end-stage AIDS dementia complex. Grade 3 or higher nausea and/or vomiting.
  • Sensitivity to pyrimethamine.

Concurrent Medication:

Excluded:

  • On-going therapy with clindamycin, fansidar, methotrexate, trimetrexate, spiramycin, azithromycin, clarithromycin, 566C80, and/or sulfa agents other than anti-PCP agents.

Patients with the following are excluded:

  • History of ocular, pulmonary, or central nervous system (CNS) toxicity.
  • CNS lesions or history of CNS lesions.
  • Neurologic deficits except peripheral neuropathy.
  • Mild, moderate, severe, or end-stage AIDS dementia complex. Grade 3 or higher nausea and/or vomiting.
  • Sensitivity to pyrimethamine.
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

Trial Site Locations

Total: 16 locations

1

Community Consortium of San Francisco

San Francisco, California, United States, 94110

Status Unknown

2

Denver CPCRA / Denver Public Hlth

Denver, Colorado, United States, 802044507

Status Unknown

3

Hill Health Corp

New Haven, Connecticut, United States, 06519

Status Unknown

4

Wilmington Hosp / Med Ctr of Delaware

Wilmington, Delaware, United States, 19899

Status Unknown

5

AIDS Research Consortium of Atlanta

Atlanta, Georgia, United States, 30308

Status Unknown

6

AIDS Research Alliance - Chicago

Chicago, Illinois, United States, 60657

Status Unknown

7

Louisiana Comm AIDS Rsch Prog / Tulane Univ Med

New Orleans, Louisiana, United States, 70112

Status Unknown

8

Comprehensive AIDS Alliance of Detroit

Detroit, Michigan, United States, 48201

Status Unknown

9

Henry Ford Hosp

Detroit, Michigan, United States, 48202

Status Unknown

10

North Jersey Community Research Initiative

Newark, New Jersey, United States, 071032842

Status Unknown

11

Addiction Research and Treatment Corp

Brooklyn, New York, United States, 11201

Status Unknown

12

Clinical Directors Network of Region II

New York, New York, United States, 10011

Status Unknown

13

Harlem AIDS Treatment Group / Harlem Hosp Ctr

New York, New York, United States, 10037

Status Unknown

14

Bronx Lebanon Hosp Ctr

The Bronx, New York, United States, 10456

Status Unknown

15

Portland Veterans Adm Med Ctr / Rsch & Education Grp

Portland, Oregon, United States, 972109951

Status Unknown

16

Richmond AIDS Consortium

Richmond, Virginia, United States, 23298

Status Unknown

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

N/A

Allocation

N/A

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Clinical programs for clinical research on AIDS: description of a randomized prospective study of clindamycin versus pyrimethamine for prevention of Toxoplasma gondii infection.

M A Jacobson, C L Besch, C Child...

https://pubmed.ncbi.nlm.nih.gov/1676364

Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS.

M A Jacobson, C L Besch, C Child...

https://pubmed.ncbi.nlm.nih.gov/1346413

Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS.

M A Jacobson, C L Besch, C Child...

https://pubmed.ncbi.nlm.nih.gov/8106772